{"filings":[{"id":91452,"accession_number":"0001127537-26-000020","cik":1127537,"company_name":"Pulmonx Corp","ticker":"LUNG","form_type":"8-K","filed_at":"2026-04-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pulmonx Q1 revenue falls 9% YoY to $20.6M; net loss $13.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Worldwide revenue $20.6M (-9% YoY, -12% constant currency); U.S. $13.3M (-7%), international $7.3M (-12%).","Ex-China international revenue grew 22% YoY; China sales paused awaiting registration renewal.","Gross margin improved to 78% (vs 73% Q1 2025); total op. expenses $29.0M (-6% YoY).","Adjusted EBITDA loss $8.5M; net loss $13.7M ($0.33 per share) vs $14.4M ($0.36) a year ago.","FY 2026 outlook reaffirmed: revenue $90-92M, gross margin ~75%, opex $113-115M, cash burn ~$23M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":20586000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":65045292.90445859,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101535,"accession_number":"0001193125-26-092064","cik":1127537,"company_name":"Pulmonx Corp","ticker":"LUNG","form_type":"8-K","filed_at":"2026-03-05T23:59:59+00:00","items":["1.01","1.02","2.03","3.02","9.01"],"status":"ready","headline":"Pulmonx enters $60M secured credit facility with Perceptive; draws $40M upfront","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$60M senior secured term loan from Perceptive; $40M drawn at closing, up to $20M additional tranches tied to $92.5M and $100M revenue milestones.","Interest rate: SOFR + 7.00% margin (minimum SOFR floor 3.75%); up to 2% margin can be paid-in-kind for 36 months.","Issued warrants to Perceptive for 1M shares at $1.92 (25% premium to 10-day VWAP); additional warrants on delayed draw fundings.","Maturity March 2, 2031; prepayment premium of 2-10% if within first 4 years; exit fee of 1.5%; minimum liquidity covenant of $4M.","Repaid and terminated existing CIBC credit agreement; no termination fees."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":65045292.90445859,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101534,"accession_number":"0001127537-26-000003","cik":1127537,"company_name":"Pulmonx Corp","ticker":"LUNG","form_type":"8-K","filed_at":"2026-03-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pulmonx Q4 revenue declines 5% YoY; full year up 8%; guides flat FY2026 revenue $90-92M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 revenue $22.6M, down 5% YoY (down 7% constant currency); US revenue fell 11% to $14.1M.","Full year 2025 revenue $90.5M, up 8% YoY (7% constant currency); international revenue up 23% to $33.5M.","Net loss improved: Q4 net loss $10.4M ($0.25/sh) vs $13.2M ($0.33/sh); full year loss $54.0M vs $56.4M.","Secured up to $60M in new 5-year interest-only credit facility extending debt maturity to 2031; cash $69.8M at year end.","FY2026 guidance: revenue $90-92M (roughly flat); gross margin ~75%; operating expenses $113-115M; cash burn ~$23M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":65045292.90445859,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117878,"accession_number":"0001127537-25-000058","cik":1127537,"company_name":"Pulmonx Corp","ticker":"LUNG","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pulmonx Q3 rev $21.5M (+5%), net loss $14.0M; guides FY rev $89-90M; adds COO role","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Worldwide revenue $21.5M (+5% YoY); US $14.0M (+1%), Intl $7.5M (+15%).","Gross margin 75% vs 74% YoY; net loss $14.0M ($0.34/share) vs $14.1M ($0.36) YoY.","Adjusted EBITDA loss $8.2M vs $8.1M YoY; cash $76.5M.","FY2025 revenue guidance narrowed to $89-90M; operating expenses $125-126M incl ~$21M SBC.","Glen French reappointed CEO; Derrick Sung appointed COO & CFO."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":67899000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":65045292.90445859,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117877,"accession_number":"0001127537-25-000052","cik":1127537,"company_name":"Pulmonx Corp","ticker":"LUNG","form_type":"8-K","filed_at":"2025-10-27T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Pulmonx reappoints Glen French as CEO and Derrick Sung as COO/CFO; Q3 preliminary revenue ~$21.5M","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Glen French (former CEO 2014-2024) reappointed President and CEO; Derrick Sung (former CFO) appointed COO and CFO effective Nov 3, 2025.","Steve Williamson and Mehul Joshi resigned as CEO and CFO; each will serve as advisors through Dec 1, 2025; departures not due to any disagreement.","Preliminary Q3 2025 revenue expected approximately $21.5M; full results and earnings call rescheduled to Nov 12, 2025.","Williamson receives $600K severance plus COBRA; Joshi receives $347,625 plus COBRA as separation compensation.","French receives $625K base salary, 100% target bonus, RSU for 1.2M shares, and PSU for 800K shares with $4.00 stock price performance condition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":65045292.90445859,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134332,"accession_number":"0001127537-25-000041","cik":1127537,"company_name":"Pulmonx Corp","ticker":"LUNG","form_type":"8-K","filed_at":"2025-07-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pulmonx Q2 revenue up 15% to $23.9M but cuts FY2025 guidance to $90-92M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $23.9M (+15% YoY); U.S. $14.7M (+6%), International $9.1M (+32% constant currency +27%).","Net loss $15.2M ($0.38/sh) vs $15.3M ($0.39/sh) prior year; Adjusted EBITDA loss $8.4M vs $7.6M.","Full-year 2025 revenue guidance cut to $90-92M from $96-98M; OpEx lowered to $128-130M from $133-135M.","Gross margin 72% vs 74% prior year; cash, cash equivalents & marketable securities $84.2M.","Added 12 new Zephyr Valve U.S. treatment centers, trained 26 physicians; over 20k first-time patient engagements."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.74,"consensus_revenue_estimate":null,"consensus_revenue_actual":46397000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":65045292.90445859,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151144,"accession_number":"0001127537-25-000028","cik":1127537,"company_name":"Pulmonx Corp","ticker":"LUNG","form_type":"8-K","filed_at":"2025-05-23T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Pulmonx stockholders reelect three directors; say-on-pay passes by slim margin","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All three Class II nominees elected: Ferrari (16.97M for, 11.95M withheld), Florin, Williamson.","Say-on-pay approved with 14.71M for vs 14.20M against (50.9% support); 4.40M broker non-votes.","Ratification of BDO USA as auditor received 33.03M for, 0.28M against.","About 82.8% of outstanding shares (33.3M of 40.2M) were represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":65045292.90445859,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151143,"accession_number":"0001127537-25-000023","cik":1127537,"company_name":"Pulmonx Corp","ticker":"LUNG","form_type":"8-K","filed_at":"2025-04-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pulmonx Q1 2025 revenue $22.5M (+20% YoY); net loss $14.4M; reaffirms FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Worldwide revenue of $22.5M, up 20% YoY (21% constant currency); U.S. $14.2M (+11%), international $8.3M (+39%).","Net loss $14.4M ($0.36 per share) vs $13.7M ($0.36) in Q1 2024; adjusted EBITDA loss $8.5M vs $8.0M.","Reaffirms FY2025 revenue guidance $96M-$98M; expects gross margin ~74% and OpEx $133M-$135M.","U.S. DOJ declined to intervene in case against Pulmonx and closed the civil investigative demand.","Amended CIBC loan to extend interest-only period through October 2027; cash & securities $88.7M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":22538000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":65045292.90445859,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170035,"accession_number":"0001127537-25-000003","cik":1127537,"company_name":"Pulmonx Corp","ticker":"LUNG","form_type":"8-K","filed_at":"2025-02-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pulmonx reports record Q4 revenue $23.8M (+23% YoY) and FY2024 revenue $83.8M (+22%); FY2025 guidance $96-98M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record Q4 2024 worldwide revenue $23.8M, up 23% YoY; U.S. revenue $15.9M (+16%), international $7.9M (+42%).","Full year 2024 revenue $83.8M, up 22% YoY; net loss $56.4M ($1.44/shr) narrowed from $60.8M ($1.60/shr) in 2023.","Adjusted EBITDA loss improved to $31.3M in 2024 from $39.0M in 2023; gross margin stable at 74%.","Cash and equivalents $101.5M at year-end 2024; added 11 new U.S. Zephyr Valve treatment centers in Q4.","FY2025 revenue guidance $96-98M (15-17% growth); operating expenses $133-135M including $22M stock comp."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":83789000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":65045292.90445859,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187055,"accession_number":"0001127537-24-000082","cik":1127537,"company_name":"Pulmonx Corp","ticker":"LUNG","form_type":"8-K","filed_at":"2024-10-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pulmonx Q3 2024 revenue $20.4M (+15% YoY), net loss $14.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Worldwide revenue $20.4M, up 15% YoY; U.S. revenue $13.8M (+17% YoY); international $6.6M (+12%).","Gross margin 74% unchanged YoY; net loss $14.1M ($0.36 loss per share) vs $14.9M ($0.39) in Q3 2023.","Adjusted EBITDA loss $8.1M vs $9.0M in Q3 2023; cash & marketable securities $107.8M as of Sep 30.","Full-year 2024 revenue guidance reaffirmed $81M-$84M; op ex guidance narrowed to $122M-$124M.","Added 15 new Zephyr Valve U.S. treatment centers; AeriSeal CONVERT trial showed 77.6% conversion rate."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":60024000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":65045292.90445859,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203585,"accession_number":"0001127537-24-000073","cik":1127537,"company_name":"Pulmonx Corp","ticker":"LUNG","form_type":"8-K","filed_at":"2024-07-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pulmonx reports record Q2 revenue $20.8M (+21% YoY); net loss narrows to $15.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Worldwide revenue $20.8M, up 21% YoY; U.S. revenue $13.9M (+26%); International $6.9M (+12%).","Net loss $15.3M ($0.39/share) vs $16.2M ($0.43) in Q2 2023; adjusted EBITDA loss $7.6M vs $10.3M.","Gross margin held at 74%; operating expenses $30.9M, including $1.7M one-time software impairment.","Added 17 new U.S. Zephyr Valve treatment centers; first U.S. patients treated in AeriSeal CONVERT II trial.","Full-year 2024 guidance reaffirmed: revenue $81-84M, gross margin 74-75%, opex $127-129M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.75,"consensus_revenue_estimate":null,"consensus_revenue_actual":39637000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":65045292.90445859,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220079,"accession_number":"0001127537-24-000063","cik":1127537,"company_name":"Pulmonx Corp","ticker":"LUNG","form_type":"8-K","filed_at":"2024-05-23T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Pulmonx extends and expands headquarters lease through 2035, adds 25,254 sq ft","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Extended lease for 24,591 sq ft at 700 Chesapeake Dr to July 31, 2035; monthly base rent starts at $113,118.60 Aug 2025.","Will add 25,254 sq ft at 200 Chesapeake Dr effective June 1, 2028; monthly rent starts at $107,329.50 with 3.5% annual escalations.","Sublease for Expansion Premises with Genomic Health runs through May 31, 2028; then direct lease with Landlord begins.","Two five-year extension options granted for the combined 49,845 sq ft premises.","Four-month rent abatement on Existing Premises (Aug–Nov 2025) valued at $452,474.40."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":65045292.90445859,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220078,"accession_number":"0001127537-24-000057","cik":1127537,"company_name":"Pulmonx Corp","ticker":"LUNG","form_type":"8-K","filed_at":"2024-05-17T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Pulmonx annual meeting elects directors; say-on-pay passes with narrow margin","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Glendon E. French re-elected with 16.9M for vs 13.7M withheld; Tiffany Sullivan with 16.7M for vs 13.9M withheld.","Ratification of BDO USA as auditor approved: 34.3M for, 38.9K against.","Non-binding advisory vote on executive compensation approved: 16.3M for, 14.3M against, 3.8M broker non-votes.","Broker non-votes of 3.8M shares present on director election and say-on-pay proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":65045292.90445859,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220077,"accession_number":"0001127537-24-000045","cik":1127537,"company_name":"Pulmonx Corp","ticker":"LUNG","form_type":"8-K","filed_at":"2024-05-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pulmonx Q1 revenue $18.9M (+30% YoY); net loss narrows to $13.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $18.9M, up 30% YoY (29% constant currency); U.S. revenue $12.9M (+38%).","Net loss $13.7M ($0.36 per share) versus $15.9M ($0.42) in Q1 2023; Adjusted EBITDA loss $8M vs $11.2M.","Gross margin 75% (vs 73% YoY); FY 2024 revenue guidance reaffirmed $81M-$84M; operating expenses guidance tightened to $127M-$129M.","Cash and equivalents $120.4M; clinical milestones: first AeriSeal CONVERT II patient and first Japanese Zephyr post-approval patient."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":18854000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":65045292.90445859,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}